|
Corporate Presentation - 2Q'20
|
|
Webcast: Rezolute's Keith Vendola Presents - Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism in New York City at BIO CEO, February 10, 2020
|
|
Webcast: Rezolute's Keith Vendola Presents Rezolute in San Francisco at Biotech Showcase, January 13, 2020
|
|
Interview: Rezolute's Keith Vendola with Proactive's Christine Corrado at 2019 BIO Investor Forum Conference, October 22, 2019
|
|
Rezolute profiled in Nature’s BioPharma Dealmakers, Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 editions
|